PREvention of VENous ThromboEmbolism Following Radical Prostatectomy
The PREVENTER Trial aims to compare the use of perioperative pharmacologic prophylaxis (subcutaneous heparin) with intermittent pneumatic compression devices (IPCs) to the use of IPCs alone for the prevention of venous thromboembolism (VTE) after radical prostatectomy (RP).
Checked against the public recordLast updated Aug 5, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Prevention
- Study type
- Interventional
- Phase
- Phase 4
- Sponsor
- Johns Hopkins University
- Interventions being studied
- Drug: Subcutaneous Heparin
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Men 18-100 years of age with histologically confirmed prostate cancer of any stage undergoing RP * Patients who would have otherwise been eligible to receive routine post-RP care Exclusion Criteria: * Active treatment for VTE * Patients judged by patients' urologist, primary care doctor, or in the preoperative evaluation center (PEC) to be unsafe to forgo pharmacologic prophylaxis or systemic anticoagulation postoperatively (whether or not patients are on systematic anticoagulation for indications other than VTE) * Known adverse reactions to heparin (heparin-induced thrombocytopenia or any allergy) * Epidural analgesia * Spinal anesthesia * Participation in a different trial that increases a patient's risk of VTE
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Johns Hopkins HospitalBaltimore, Maryland
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 5, 2020. Always confirm current availability with the study team.